This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
|Zacks Rank||Definition||Annualized Return|
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at firstname.lastname@example.org or call 800-767-3771 ext. 9339.
Supernus Pharmaceuticals, Inc. (SUPN - Snapshot Report) recently announced encouraging top-line results from a phase IIb study, which is evaluating its attention deficit and hyperactivity disorder (ADHD) candidate, SPN-810, across three doses. The company plans to advance the candidate into phase III trials and will meet the US Food and Drug Administration (FDA) to discuss the trial design and protocol for the same.
The multicenter randomized, double-blind, placebo controlled trial enrolled 121 children aged between 6 to 12 years with ADHD and characterized by impulsive aggression that is insufficiently controlled by optimal stimulant and psychosocial treatment. The study aims to identify the optimum dose of the candidate in children of different weight groups.
Reduction in impulsive aggression, measured with change in the score of the Retrospective - Modified Overt Aggression Scale (R-MOAS) and the rate of remission of aggression were the primary endpoints of the study.
The candidate demonstrated promising efficacy at low and medium doses withdoses with a reduction in the R-MOAS scores of of 62.6% and 57.9%, respectively, in score for the R-MOAS. .versus placebo. Low and medium dose of SPN-810 also showed significant reduction in rate of remission of aggression. However, we note that the high dose of SPN-810 did not exhibit efficacy with statistical significance.
Although the competition in the US ADHD market is severe, with generic versions of Johnson & Johnson's (JNJ - Analyst Report) Concerta and Novartis’ (NVS - Snapshot Report) Ritalin available in the market, we note that currently there are no products approved for the treatment of impulsive aggression in ADHD patients.
We currently have a Neutral recommendation on Supernus. The stock carries a Zacks #3 Rank (Hold rating) in the short run.
Please login to Zacks.com or register to post a comment.